Investigators systematically evaluate the efficacy differences of existing treatment regimens for IgA nephropathy.

Purespring Therapeutics has received approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead programme, PS-002, to treat IgA nephropathy (IgAN). Approval from the UK ...

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval ...

Q2 2025 Earnings Call Transcript August 6, 2025 Travere Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Management expects continued revenue growth driven by robust FILSPARI demand in IgA nephropathy and potential additional milestone payments. Cline said, "we expect continued revenue growth driven by ...

On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; ...

Taiwan region became the last region across all Everest’s territories to grant full approval for NEFECON (R), together with Mainland China, Singapore, Macao SAR, Hong Kong SAR and South Korea. This ...

Now, it’s worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for ...

Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R)'is ...

Analysts are estimating that Travere Therapeutics will report an earnings per share (EPS) of $-0.12. The announcement from ...

As global markets grapple with renewed trade tensions and economic uncertainties, Asian equities present a mixed landscape, with some indices experiencing declines amid these challenges. In this ...

VX-993 was generally safe and well tolerated at all doses studied in the trial. The overall incidence of adverse events on VX-993 was similar to placebo. The majority of the AEs were mild or moderate ...